Volume 4, Issue 4 (2018)                   Pharm Biomed Res 2018, 4(4): 25-31 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Peccinini R, Alzate M, Ferraz M, Franchin T, Oliveira J, Candido C, et al . Kinetic disposition of ursolic acid in rats. Pharm Biomed Res. 2018; 4 (4) :25-31
URL: http://pbr.mazums.ac.ir/article-1-205-en.html
Department of Natural Active Principles and Toxicology, School of Pharmaceutical Sciences, UNESP- Univ Estadual Paulista, Araraquara, Sao Paulo, Brazil
Abstract:   (686 Views)
Benznidazole and nifurtimox are two drugs that are used to treat trypanosomiasis. Ursolic acid (UA) reportedly acts against trypomastigotes and intracellular amastigotes of Trypanosoma cruzi. Accordingly, it is expected to have therapeutic benefits in the treatment of trypanosomiasis. Therapeutic application of a compound requires the investigation of its pharmacokinetic properties in order to obtain relevant information to design the in vivo assays and dose regimen. Regarding this, the current study aimed to evaluate the pharmacokinetic profile of UA administered to rats at different doses and routes (i.e., 1 mg/kg intravenously and 20 and 50 mg/kg orally). According to the results, the oral bioavailability was significantly different between the two groups that orally received the UA doses of 20 mg/kg (2.8%) and 50 mg/kg (1.55 %). The result suggests the interference of the poor aqueous solubility of UA on its absorption process. The pharmacokinetic parameters related to the distribution and elimination were similar. Accordingly, it can be concluded that at this dose range, there is no saturation in this process rendering a linear the kinetics. The pharmacokinetic properties of UA were observed in this study indicated that the improvement of water solubility in this medicine through pharmacotechnical resources would be a great utility for its oral bioavailability and development of a product with the potential therapeutic application. The oral administration of this new pharmaceutical formulation should be investigated in future studies.
Full-Text [PDF 1075 kb]   (261 Downloads)    
Type of Study: Research | Subject: Pharmacology

Add your comments about this article : Your username or Email:

Send email to the article author

© 2019 All Rights Reserved | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb